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ϯ͘ ďƐƚƌĂĐƚ
!e "rst part of this thesis summarizes the current literature on small choroidal melanomas 
(CMs). Although the aetiology of this disease remains unknown, many risk factors have 
been reported. Di#erentiation from the more common choroidal naevi is generally clinical, 
and several typical characteristics of the malignant tumour have been used as a diagnostical 
tool. When the di#erentiation cannot be made clinically or by biopsy, the remaining option 
is to observe for growth that signals malignancy.1-3%Small posterior tumours, in particular, 
have frequently been observed for growth because treatment would most likely a#ect 
vision. However, observation before treatment might increase the risk for metastases.4
Small CMs are typically treated conservatively, and enucleation is no longer a generally 
accepted alternative, partly because these tumours are thought to be able to micrometastasise 
years before diagnosis.5 !e primary aims when managing small malignant CMs are to 
destroy the tumour and prevent local recurrences that might be associated with an increased 
risk for metastases.6-8 Eye-preserving treatments frequently allow for the preservation 
of useful vision as well. Several options are available for treating small CMs. In Finland, 
the majority of CMs are treated with episcleral plaque brachytherapy. Ruthenium106 
brachytherapy is an e#ective choice for small melanomas because the dose distribution is 
ideal for treating tumours with a thickness of up to 5.4 mm.9 
!e second and main part of this thesis summarizes the recent Finnish contributions to this 
"eld. !e research presented in this thesis starts by retrospectively examining the treatment 
results from 10-mm ruthenium plaque (Study I), leading to a comparative study looking at 
the treatment results of both 10-mm round radioactive plaque (CCX)  and 15-mm round 
radioactive plaque (CCA), with the aim to see whether and when it is safe to reduce vision- 
threatening radiation side-e#ects by using a smaller plaque (Study II) when treating small 
CMs less than 10 mm in their largest basal diameters (LBDs). !e smallest 10-mm plaque 
delivers less scattered radiation compared with a 15-mm plaque or larger. Previously, it 
was not known whether a smaller radiation area and less scattered radiation could a#ect 
the recurrence rate, preservation of useful vision, and frequency of side-e#ects. !is thesis 
found that the recurrence and complication rates were comparable between patients 
treated with the 10-mm or 15-mm plaque, but vision was more e#ectively preserved a&er 
treatment with the 10-mm plaque when the tumour was located close to the foveola. An 
eccentric location of the plaque was a risk factor for a local recurrence with both plaques. 
!is study supports the treatment of small posterior CMs close to fovea with 10-mm rather 
than 15-mm plaque.
!e challenge of diagnosing small CMs before they have the capacity to disseminate led 
to the search for the smallest size of a CM that had been reported to metastasize and an 
attempt to "nd out whether melanomas that disseminated and melanomas that did not 
Abstract
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disseminate di#ered from each other clinically. As the Finnish population is not su'ciently 
large to collect data for this study, a retrospective collaboration study was done with the 
European% Ocular Oncology Group (OOG) (Study III). Ten ocular oncology services 
submitted the data on all their patients with a CM of 3%mm or less in thickness and 9%mm 
or less in LBD who were treated and who subsequently developed%metastases. !is study 
found that CMs less than 3%mm in LBD are unlikely to metastasize. Observation without 
treatment beyond this limit might impair survival. Clinical characteristics of small fatal 
choroidal melanomas (SFCMs) did not di#er from those of non-fatal CMs of a similar size: 
clinical characteristics predicting metastasis could not be identi"ed.
Due to inspiration from Study III, ways to alternatively diagnose small melanomas before 
they get the capacity to disseminate were examined. !e growth rates and tumour doubling 
times (TDT) of incipient CMs were calculated (Study IV). Short TDT and a fast growth rate 
combined with the calculated age at tumour origin a&er puberty supported a melanoma 
diagnosis. !ese were the nine smallest presumed CMs reported at that point. !e earlier 
diagnosis enabled treating these patients with less invasive transpupillary thermotherapy 
(TTT), of which preliminary results are shared in this thesis. !e reported growth 




Tämän väitöskirjan ensimmäinen osa kokoaa kirjallisuuskatsaukseksi suonikalvon 
melanoomaa käsittelevät ajankohtaiset julkaisut. Vaikka suonikalvon melanooman etiologia 
on avoin, monia sille altistavia tekijöitä tunnetaan. Melanooman erottaminen yleisemmästä 
hyvänlaatuisesta luomesta tapahtuu useimmiten kasvaimen kliinisten piirteiden 
perusteella. Jos kasvaimen pahanlaatuisuutta ei voida kliinisten piirteiden tai biopsian 
avulla varmentaa, kasvainta seurataan mahdollisen kasvun havaitsemiseksi.1-3% Erityisesti 
pieniä silmän takaosassa sijaitsevia kasvaimia seurataan diagnoosin ollessa epävarma, 
sillä hoito todennäköisimmin heikentää näköä. Kasvainten seuraaminen ennen hoitoa voi 
suurentaa riskiä etäpesäkkeille.4
Pienet suonikalvon melanoomat hoidetaan tavallisesti paikallisesti eikä silmänpoisto ole 
enää yleisesti hyväksytty hoitokäytäntö, koska näiden syöpäkasvainten ajatellaan olevan 
leviämiskykyisiä jo vuosia ennen diagnoosia.5 Hoidon tärkein tavoite on tuhota kasvain ja 
estää kasvaimen paikallinen uusiutuma, mikä itsessään on riski etäpesäkkeille.6-8 Silmän 
säästävä hoito voi myös mahdollistaa käyttökelpoisen näkökyvyn säilyttämisen. Useista 
hoitovaihtoehdoista Suomessa on yleisimmin käytössä kovakalvon pinnalle asetettava 
sädehoitolevy. Rutenium106-isotooppi soveltuu hyvin alle 5.4 mm paksujen kasvainten 
hoitoon ideaalisen annosjakaumansa vuoksi.9 
Tämän väitöskirjan toinen osa kokoaa viimeisimmät suonikalvon melanoomien 
diagnostiikkaa ja hoitoa käsittelevät kotimaiset julkaisut yhdeksi kokonaisuudeksi. Tässä 
väitöskirjassa esitetty tutkimus alkoi hoitotuloksien selvityksellä, jossa pienten alle 10 
mm halkaisijaltaan olevien kasvainten hoitoon oli käytetty 10-mm halkaisijaltaan olevaa 
ruthenium-sädehoitolevyä (osatyö I). Tutkimusta jatkettiin tekemällä vertaileva työ 10 mm 
(CCX) ja 15 mm sädehoitolevyillä (CCA) saaduista hoitotuloksista (osatyö II). Pienemmän 
halkaisijaltaan 10 mm levyn tavoitteena on säästää näkökykyä, koska pienemmän 
säteilevän alueen lisäksi pienempi levy tuottaa puolet vähemmän hajasäteilyä. Aiemmin 
ei ollut tiedossa vaikuttaako pienempi sädehoidettava alue ja pienempi hajasäteilyn määrä 
hoitotuloksiin niin kasvaimen uusiutumisen kuin näkökyvyn säilymisenkin suhteen. 
Paikallisissa kasvainten uusiutumisissa tai hoitoon liittyvissä komplikaatioissa ei havaittu 
eroa ryhmien välillä, mutta näkökykyä onnistuttiin säilyttämään hieman paremmin, 
kun hoitoon valittiin 10 mm levy. Tämä tutkimus suosittelee pienten silmän takaosassa 
sijaitsevien alle 10 mm halkaisijaltaan olevien kasvaimien hoitoon 10 mm halkaisijaltaan 
olevaa levyä.
Pienten suonikalvon melanoomien hoidon haasteena on diagnosoida pahanlaatuiset 
kasvaimet ennen kuin ne saavuttavat leviämiskyvyn. Asian selvittämiseksi käynnistettiin 
monikeskustutkimus, jossa 10 eurooppalaista silmäkasvaimia hoitavaa keskusta lähetti 
tiedot alle 3 mm paksuista ja alle 9 mm halkaisijaltaan olevista suonikalvon melanoomista, 
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jotka olivat lähettäneet etäpesäkkeitä. Aineistosta selvitettiin pienimmän etäpesäkkeitä 
lähettäneen suonikalvon melanooman koko ja etäpesäkkeitä lähettäneiden kasvainten 
kliinisiä piirteitä verrattiin kasvaimiin, jotka eivät olleet levinneet. Tulosten perusteella 
alle 3 mm halkaisijaltaan olevat kasvaimet eivät todennäköisesti vielä lähetä etäpesäkkeitä. 
Kasvavan muutoksen seuranta tämän raja-arvon jälkeen voi altistaa potilaan etäpesäkkeille. 
Kasvainten kliinisten piirteiden perusteella ei voi arvioida etäpesäkkeiden kehittymisen 
riskiä.
Selvitystä siitä, onko suonikalvon melanoomat mahdollisesta diagnosoida ennen kuin 
ne saavuttavat leviämiskyvyn jatkettiin. Joukko pieniä suonikalvon muutoksia, jotka 
ovat nopean kasvutaipumuksensa vuoksi todennäköisimmin melanoomia analysoitiin. 
Muutosten kasvunopeudet ja kahdentumisajat laskettiin ja kasvunopeuden perusteella 
arvioitiin potilaan ikä, jolloin kasvain olisi ollut havaittavissa. Nopeat kasvunopeudet 
ja kahdentumisajat verrattuna hyvänlaatuisiin luomiin ja laskennallinen ikä luomien 
havaitsemiselle aikuisiällä tukevat melanomadiagnoosia. Aiempaa varhaisempi diagnoosi 
mahdollistaa potilaiden hoitamisen transpupillaarisella lämpölaserhoidolla sädehoidon 
sijaan, jolloin voidaan välttyä säteilyn aiheuttamilta haittavaikutuksilta. Raportoitua tapaa 





Uveal melanoma (UM) is the second most common intraocular malignancy a&er 
retinoblastoma worldwide but the most common in Caucasians and adults.10-14 Up to one 
half of patients with UM develop metastatic disease within 10 years of diagnosis15-21, and 
the median survival a&er metastases has ranged from 6 to 13 months.19,22,23 Early diagnosis 
and treatment of UM are crucial because a larger size impairs prognosis.14,24-30 However, 
di#erentiation between benign naevi and small malignant CM can be di'cult, as there is 
a spectrum of small choroidal melanocytic lesions ranging from benign lesions – naevi – 
with minor growth potential and no clinical risk factors to obviously malignant lesions with 
documented growth, several risk factors, and signi"cant risk for metastatic disease.29,31,32 
Management of small choroidal tumours is further complicated by the small number of 
naevi that transform into cancer.26,29,33
Treatment of low-risk small choroidal melanocytic lesions is controversial because the 
signi"cant majority of such tumours tend to remain stable and are likely benign choroidal 
naevi that will not spawn a melanoma during the lifetime of the patient.1,34-38 Certain 
clinical factors have been shown to predict growth that helps clinicians to distinguish small 
CMs from benign lesions.28,29,31,32,39-41 Such factors include, in particular, tumour thickness 
over 2 mm, subretinal $uid (SRF), symptoms, orange pigment (OP), and the margin either 
touching or being within 2 disc diameters (DD) of the optic disc.27,42 When risk factors are 
lacking, these tumours are followed-up in order to detect growth to ascertain malignancy 
and to justify treatment.34 Particularly small posterior tumours are frequently observed for 
growth because treatment will most likely compromise vision. Tumour growth over a short 
period is considered a hallmark of CM although benign choroidal naevi can demonstrate 
slow growth over a period of many years to several decades as well, and the presence of 
such a slow growth in the absence of other risk factors is not an indicator for treatment.43 
Follow-up without treatment may theoretically have an e#ect on prognosis and expose 
the patient to metastatic disease if the tumour is a melanoma.4 !e dilemma is that, while 
potentially malignant tumours that can spread systemically should be treated without delay, 
their identi"cation can be challenging. Additionally, treatment of benign tumours does not 
bene"t the patient and will likely deteriorate the patient’s vision. !e goal is to identify and 
only treat melanocytic lesions that are likely to spread to thus destroy these lesions before 
they do so. 
A majority of CMs are treated conservatively either with episcleral plaque radiotherapy 
alone or in combination with TTT.44-50 Enucleation does not improve prognosis because 
tumours that have the capacity to disseminate are estimated to micrometastasise years 
before diagnosis.5 !e primary goals in the management of small malignant melanomas 
are to destroy the tumour and to prevent local recurrences that might be associated 
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with an increased risk for metastases.6,51 Conservative treatment frequently allows for 
the preservation of useful vision. However, small CMs are frequently located posteriorly 
where the risk of vision loss is higher because of treatment side-e#ects. Tumours must 
be e#ectively treated to a su'cient degree to prevent local and systemic recurrence, 
simultaneously minimizing toxicity to healthy tissues.
In TTT, 810 nm diode laser energy is directed through a dilated pupil to the tumour apex, 
causing hyperthermia.48 As a primary treatment TTT is controversial because of high local 
recurrence rates.52-60 It could be a treatment of choice in a selected group of patients with 
small choroidal tumours with minimal risk factors located close to but outside the central 
macula.53,61
!e research behind the present thesis aimed to determine the size limit of a small choroidal 
melanoma becoming capable of dissemination, describe the clinical tumour characteristics 
of metastasizing small tumours, and report TDTs and growth rates of incipient tumours in 
order to discover diagnostic criteria that could establish when small pigmented tumours 
should be treated. !is thesis futher reports the results of treatment with primary Ru106 
brachytherapy using 10-mm and 15-mm plaques and presents the comparison between 







!e incidence of UM varies by race, latitude, age, and gender. It predominantly a#ects 
white Caucasians.62-64 !e mean age-standardized incidence rate is 5.1 cases per million 
per year.15 !e incidence rate varies inside Europe, with the highest being in Northern 
Europe at approximately 8–9.5 per million and, in Finland, as high as 12 per million65, as 
compared to 4–6 million in Central Europe and 1.7–2 per million in Southern Europe.66,67 
In the United States and Canada, the mean incidence rate is 4–6 per million,14,15,62,68,69 with 
the highest incidence rate occurring in non-Hispanic whites at 6 per million as compared 
to black Americans and Asians at 0.3 and 0.4 per million, respectively.70 !e incidence rate 
in Australia is as high as in Northern Europe at 8 per million.71 Standardized incidence 
rate estimates suggest that 7,000 new patients are diagnosed annually worldwide.66 !e 
standardized incidence of UM has remained stable over the years14,15,20,72,73 in contrast with 
the rising incidence of cutaneous74 and conjunctival melanoma75. However, the incidence 
of UM in Finland has increased in 20 years from approximately 8 to 12 per million due to 
an increasing overall population age.65,67 !e incidence rate increases with age, peaks at the 
age of 7010-12, and plateaus a&er 75 years of age12,14,15,66. !e median age range at diagnosis 
is 59–62 years.12,15,64,76 !e median age slowly increased over the years to 62 years due to 
increasing life expectancy.77 !e incidence of UM in children and teenagers is rare78-80 
and increases steadily until the age of 11 years, followed by a transition to a more than 
10-times faster increase a&er the age of 17.81 Males show a slight predominance in crude 
incidence.10,64,67
ϲ͘ϭ͘Ϯ͘ WĂƚŚŽŐĞŶĞƐŝƐ
!e aetiology of UM is unknown.63 However, "ve driver mutations have been 
commonly found: BAP1, GNAQ, GNA11, SF3B1, and EIF1AX.82-89 UMs originate from 
neuroectodermal melanocytes in the middle, uveal layer of the eye wall.90 UMs are divided 
into di#erent types according to their location: anteriorly located iris melanomas and 
posteriorly located ciliary body melanomas and CMs. !e majority of UMs originate in 
the choroid (85%–90%), and remainder originate in the iris (3%–5%) and the ciliary body 
(5%–8%).67,76,91,92
UMs, although also originating from melanocytes, di#er from cutaneous melanoma and 
mucous membrane – including conjunctival – melanomas in terms of% epidemiology, 
aetiology, biology, genetics, and clinical features, including a high propensity to metastasize 
haematogenously to the liver.93 UM predominantly disseminates haematogenously because 
there is no traditional lymphatic drainage within the eye.94
Review of the literature
15
ϲ͘ϭ͘ϯ͘ ,ŽƐƚͲĂŶĚĞŶǀŝƌŽŶŵĞŶƚͲƌĞůĂƚĞĚĐŚĂƌĂĐƚĞƌŝƐƚŝĐƐ
Several predisposing factors have been identi!ed as a"ecting the occurence of UM, 
including, as aforementioned, race, age, and gender and additionally including blue eyes, 
fair skin, the inability to tan, ocular or oculodermal melanocytosis, choroidal naevi, and 
germline mutations in BAP1 or MBD4 genes.
Although light skin and a blue iris colour are established risk factors for UM95, the 
role of sun exposure is weak,63,96,97 in contrast to cutaneous melanoma.98 Long-term 
exposure to ultraviolet-radiation is not associated with the incidence of UM,99 whereas 
intermittent#exposure to ultraviolet#rays from welding has been reported to double the risk 
of the development of UM,99,100 this !nding is, however, questionable.101
Congenital ocular# melanocytosis is an important condition predisposing individuals to 
UM.102 It is a rare developmental pigmentary disorder in which the number of melanocytes 
is increased in ocular and periocular tissues. Melanomas arising from ocular melanocytosis 
are associated with more frequent genomic alterations and a double risk for metastatic 
disease.103,104
Choroidal naevi carry a small risk of transformation into CM.27-29,31,32,39-41,105-107 At least 
one in 10 melanomas originates from pre-existing naevi,108-110 which, however, exist in 
approximately 3–8% of the general population.25,26,111,112 $e annual rate for malignant 
transformation is estimated at one in 3,664 to 8,845,26,113 and the lifetime risk for malignant 
transformation is about 1%.107
Although UM generally occurs sporadically,63 BAP1 germline mutations have been 
described in families with hereditary BAP1 cancer syndrome, including UM, comprising 
0.6–6 % of UM patients depending on age.114-124 $e prevalence of  pathogenic BAP1 variants 
is reported to be 25% in Finnish familial UMs.125 Patients with BAP1 cancer syndrome have 
an increased risk of several cancers, the most frequent of which is UM.82,115,117 Patients with 
UM have over 10% risk for other malignancies, which is, to a certain extent, driven by the 
presence of germline BAP1 mutations.126
UMs are associated with a predisposing germline loss%of%function variant in the MBD4 
gene causing hypermutated tumours127-129, a variant which has a prevalence in UM patients 
that is 9.15 times more frequent than in the general population.127 $ese hypermutated 
tumours should be recognized since they may respond to checkpoint inhibitor (CPI) 
immunotherapy.118,130-132
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ϲ͘ϭ͘ϰ͘ 'ƌŽǁƚŚƉĂƚƚĞƌŶƐ
Small choroidal tumours are frequently $at or crescent in shape. A&er growing vertically, 
they become dome-shaped, and when the Bruch’s membrane ruptures, they extend into 
the subretinal space and become mushroom-shaped.90,133 !e sclera presents resistance 
to the tumour expansion, and the tumour therefore protrudes into the vitreous cavity.134 
CMs may eventually extend through existing scleral channels along nerves and vessels into 
the episclera or the orbit, an event which occasionally occur, even with small choroidal 
tumours around the optic disc,135-139 an area that is rich with intrascleral nerves and vascular 
channels.134,140,141
ϲ͘ϭ͘ϱ͘ ůĂƐƐŝĨŝĐĂƚŝŽŶŽĨƐŵĂůůĐŚŽƌŽŝĚĂůŵĞůĂŶŽŵĂ
Numerous de"nitions have been devised for each CM size category.18,142 !e use of 
classi"cations should allow for the comparison of treatments for equivalently sized and 
staged tumours. !e Collaborative Ocular Melanoma Study (COMS) has de"ned a small 
CM as being 1–2.5 mm in thickness and 5–16 mm in LBD; tumours smaller than this 
are regarded as probable naevi.143 It has been estimated that when the LBD is 5–6 mm, 
about 70 choroidal naevi are diagnosed for each melanoma, and it has been stated that few 
melanomas would be less than 5 mm in diameter.33,144
UMs have been classi"ed by size and anatomic extent which a#ect the risk for metastases 
and survival.24 According to the American Joint Committee on Cancer (AJCC) Tumour, 
Node, Metastasis (TNM) staging systems latest 7th and 8th edition,145,146 the criteria of 
tumour size caterory T1 are a thickness less than 3.0 mm if the LBD is less than 12.0 mm 
or a thickness less than 6.0 mm if the LBD is less than 9.0 mm. Tumour size category 
T2 tumours can be classi"ed as medium-sized, and the corresponding size criteria are a 
thickness less than 3 mm if the LBD is 12.1–18 mm, a thickness of 3.1–6 mm if the LBD is 
9.1–15 mm or a thickness 6.1–9 mm if the LBD is 9.1–12 mm. 145
Table 1. Current Tumour, Node, Metastasis categorization of choroidal and ciliary body 

















!e di'culty of detecting small CM relates to the diversity of small pigmented choroidal 
lesions ranging from benign naevi, via indeterminate pigmented lesions, to malignant 
melanoma.28,31,32,147 Clinical risk factors help clinicians to determine which small 
melanocytic choroidal tumours should be treated or biopsied without waiting for tumour 
growth. Lesions carrying any of these risk factors are generally referred for evaluation by a 
retinal specialist or ocular oncologist. Smaller melanomas typically show fewer risk factors 
than larger melanomas, making their diagnosis more di'cult.133
!ere is no consensus on indications for treatment of small choroidal melanocytic 
tumours. !e more risk factors are present, the more likely it is that a choroidal lesion is a 
melanoma.148 Lesions that display one risk factor have a 38% risk for growth, and those with 
two or more factors show growth in over 50% of tumours.148 When a lesion does not have 
any of these factors, the risk for growth and malignancy over 5 years is approximately 3%, 
and the tumour is more likely to be a choroidal naevus that can be monitored periodically.148 
However, the typical risk factors27,42 are not pathognomocic for malignancy.149 !e treatment 
of low-risk small choroidal lesions is controversial because a majority of these lesions will 
remain stable and likely be benign choroidal naevi.2,28,31,53 
ϲ͘Ϯ͘Ϯ͘ ůŝŶŝĐĂůƌŝƐŬĨĂĐƚŽƌƐĨŽƌĐŚŽƌŽŝĚĂůŵĞůĂŶŽŵĂ
Certain clinical signs are risk factors for tumour growth and metastasis.27,31,32,39-42,150 !ese 
independent risk factors are a tumour thickness over 2 mm, a LBD over 5 mm, SRF, ocular 
symptoms, OP, a posterior tumour marging either touching or located within 3 mm of the 
optic disc, ultrasound (US) hollowness, the absence of a halo around the tumour, and the 
absence of drusen (Fig. 1). 
A tumour thickness over 2 mm (Fig. 1) is a consistent independent risk factor for 
malignancy27-29,33,150 and is associated with the class 2 gene expression pro"le (GEP)149 
(see below – 6.3.3: Cytogenetic prognosticators). Tumours less than1.0 mm in thickness 
are most likely naevi27 and there  are approximately 125 naevi for each melanoma in the 
thickness range between 1.5–2 mm, but only 25 naevi for each melanoma in the range of 
2–2.5 mm, and 5 in the range of 2.5–3 mm.144 !e rate of melanoma-related metastasis at 
10 years gradually increases by each millimetre from 6% to 51% when thickness increases 
from the 0–1.0mm to >10.0mm, respectively.76 Additionally, a tumour diameter over 5 mm 
has been described as an independent risk factor for malignancy.150
Clinically detectable SRF (Fig. 1) is a strong indicator of metabolic activity and 
malignancy.27,151 Optical coherence tomography (OCT) evidence of SRF has a predictive 
value in identifying tumours that have cellular activity and are likely to grow. However, 
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around 10% of choroidal naevi have been reported to present small amounts of SRF 
detectable on OCT due to the gradual atrophy of the retinal pigment epithelium (RPE) and 
loss of its pumping action that normally keeps the subretinal space dry.64,150,152-155
Small choroidal tumours can cause visual symptoms when located close to or extending 
under the fovea (Fig. 1). Since UMs are generally slowly growing tumours,20,156 these 
symptoms are generally not speci"c. !e most commonly presenting symptoms are blurred 
vision, photopsia, $oaters, a visual "eld defect, and metamorphopsia.27,108 !e development 
of symptoms is frequently indicative of growth and frequently leads to the diagnosis of 
melanoma.157 
!e RPE can display intracellular lipofuscin accumulation overlying active tumours (Fig. 
1).158,159 !is is clinically evident with biomicroscopy or  fundus auto$uorescence (FAF) of 
the posterior pole and is%described as OP over the pigmented lesions. OP appears black 
over amelanotic tumours. OP can be found in over 6–10% of benign posteriorly located 
naevi, which should be frequently evaluated for malignancy; thus, the presence of OP alone 
does not automatically indicate malignancy.105
A posterior tumour margin either touching or extending within 2 DD from the optic disc 
margin has been associated with a higher risk for malignancy.27,42 However, this location was 
reportedly no longer a signi"cant risk factor when the analysis was based on multimodal 
imaging.33
Small CMs typically have a relatively low acoustic re$ectivity on A- and B-scan US due to 
their homogenous regular structure (Fig. 1).160-162 Additionally, a regular acoustic internal 
structure and the presence of a vascularity within the lesion can be detected.160,163 !ese 
are useful when di#erentiating between choroidal metastases and haemangiomas.164 B-scan 
US is additionally instrumental in measuring tumour thickness and the LBD, as well as in 
exploring tumour shapes and the presence of an extrascleral extensions.133,165 Extraocular 
extensions of CM, which are rare in small melanomas,166 appear as echolucent nodules 
adjacent to the sclera at the tumour base.133 Choroidal naevi are frequently  excessively thin 
to be reliably evaluated with US and do not facilitate the diagnosis of thin melanomas less 
than 1 mm in thickness either.133
!e absence of a halo or overlying drusen are risk factors for growth.42 A halo is a ring 
of lighter pigmentation surrounding a choroidal lesion. !is phenomenon is generally 
associated with naevi but can occasionally be seen with melanomas.167 Drusen are an 
age-related sign of a compromised RPE that have developed over a long period of time. 
Drusens can be seen overlying choroidal lesions and are the signal of inactive, and therefore 
most likely benign, naevi. Drusen do not exclude the possibility of malignancy. !ey may 
occasionally suggest that a previous naevus has become active, particularly when they are 
unevenly distributed over the lesion.105 Drusen can additionally be an incidental "nding 
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over a choroidal tumour when they are further present in the surrounding retina as an age-
related degeneration.
Figure 1. A small choroidal melanocytic tumour with 4 clinical risk factors: symptoms 
(metamorphopsia and a visual "eld defect), on ophthalmoscopy (Le!): subretinal $uid (SRF) 
(white arrows), and orange pigment (OP) (black arrows), and on B-scan ultrasonography 
(Right): a tumour thickness over 2 mm, as well as a relatively hollow internal re$ectivity.
ϲ͘Ϯ͘ϯ͘ ůŝŶŝĐĂůĚŝĂŐŶŽƐŝƐ
Clinical risk factors are most frequently evaluated by comprehensive ophthalmic 
examination, US, OCT, and in the case of indeterminate tumours, by serial observations 
for tumour growth as well. Other available methods for diagnostic veri"cation are di#erent 
modalities of OCT, $uorescein angiography (FAG), indocyanine green angiography (ICG), 
and FAF. For small tumours, computed tomography (CT) or magnetic resonance imaging 
(MRI) is generally not needed unless an extrascleral extension or optic nerve invasion are 
suspected.
OCT and optical coherence tomography angiography (OCTA) are non-invasive imaging 
modalities that provide a more detailed image of the retina and choroid when compared 
to US.168 OCTA provides insight into retinal vascular abnormalities related to CMs, such as 
an enlargement of the deep foveal avascular zone and a decrease in the super"cial and deep 
parafoveal capillary vascular densities, which appear to be correlated with the presence of 
SRF and to be absent in choroidal naevi.168,169 OCT technology is traditionally limited to the 
examination of posterior lesions, but newer technologies enable a view of peripheral lesions 
as well.170 Furthermore, a microscope-integrated OCT has been used intra-operatively to 
guide a biopsy in real-time, increasing the chance of obtaining an adequate sample and 
avoiding unnecessary damage.171
Enhanced depth imaging optical coherence tomography (EDI-OCT), uses spectral domain 
technology, and swept-source optical coherence tomography (SS-OCT) with faster 
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scanning engines and can image structures from the choroid to the inner sclera.172 SS-OCT 
uses longer wavelengths compared with earlier generation OCTs, enabling improved 
penetration through the RPE and examination of deeper structures.168,172
EDI-OCT, as a result of a modi"cation of the SD-OCT technique, enables the reliable 
imaging of the choroid in its full-thickness.173,174 By permitting high-resolution 
visualization of the choroid, EDI-OCT is sensitive to recognizing thin lesions and possibly 
detecting a submillimeter early melanoma that might not be apparent with US.175-177 
Typical characteristics visible on EDI-OCT include deep optical shadowing, thinning or 
compaction of the choriocapillaris, disruption of the adjacent retinal photoreceptor layer, 
SRF with or without lipofuscin deposition, and intraretinal $uid.177
FAF is a nonǦinvasive technique useful for identifying lipofuscin in pigmented choroidal 
lesions.178-180  It is based on the stimulated emission of light from naturally occurring 
$uorophores, the most signi"cant being lipofuscin.180 A majority of naevi are not hyper-
auto$uorescent.180 Naevi generally show a normal pattern of background FAF, but a 
minority of cases may reveal areas of a decreased FAF signal that is associated with chronic 
RPE degenerative features and atrophy.180,181 Nearly 90% of CMs located at the posterior pole 
show at least one focus of increased auto$uorescence.182 SRF represents a barrier between 
the photoreceptors and the RPE, preventing their normal phagocytosis. As a result, they 
accumulate on the outer retinal surface and in the subretinal space and become a  source of 
auto$uorescence.180
Invasive methods, such as FAG and ICGA, which involve the injection of an intravenous 
dye, have been used to di#erentiate melanoma from a masquerading pathology to search 
for secondary neovascularization or ischaemia or to assist in visualizing lesions obscured 
by media opacities, but non-invasive methods have replaced these methods to a certain 
extent.183,184 !e imaging of the choroidal vasculature with ICGA may reveal microvascular 
patterns that can help to di#erentiate a naevus from a melanoma through the recognition 
of the typical features of melanomas, such as an irregularity of the lesion’s margins; a 
heterogeneous, hypore$ective choriocapillaris plexus with avascular areas; hyperre$ective 
choriocapillaris rings; thick choroidal vascular networks; and choroidal vascular loops.169,185 
!e presence of haemorrhages and lipid exudation on ICGA as well as FAG are useful 
for the di#erential diagnosis of a malignant CM and choroidal metastasis as opposed to 
peripheral exudative haemorrhagic chorioretinopathy.186 Typical "ndings of CM on FAG 
include hypo$uorescence with mottled hyper$uorescence in the arterial or early venous 
phase. However, a small CM with an intact overlying RPE can demonstrate no appreciable 
abnormalities.187-189 FAG can reveal OP clumps on the surface of the tumour, where these 
clumps appear to be hypo$uorescent. SRF can be seen by the accumulation of $uorescein 
in the late frames, leading to hyper$uorescence.187-189
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ϲ͘Ϯ͘ϰ͘ KďƐĞƌǀĂƚŝŽŶĨŽƌŐƌŽǁƚŚ
Diagnosing a small CM may include observation with watchful waiting in the event that 
the diagnosis is not otherwise ensured.1-3 Observation is thought to be justi"ed and unable 
to impact prognosis39 because it has been estimated that development of micrometastases 
initiates several years before the diagnosis of a CM.190-192 However, it is not known when the 
dissemination takes place, but tumours as small as 3 mm in LBD and 1.5 mm in thickness 
have been predicted to be capable of dissemination.193 Initial observation for growth might 
be appropriate in a majority of choroidal tumours less than 2.25 mm in thickness and in 
patients under 60 years of age since a majority of those tumors will belong to GEP class 1 
(see below: 6.3.3: Cytogenetic prognosticators) and have a lower risk of metastases.149
Not all enlargement, however, represents true transformation into melanoma. Slow 
enlargement over years at a median growth rate of 0.06 mm/year has been shown to likely 
represent a benign naevus without transformation over time.43,194 It is current practice 
to consider an enlargement over 0.5 mm within 2 years to be suggestive of a malignant 
tumour.195
De novo tumours become visible a&er 20 cell divisions still being less than 1 mm in size.193 
!e development of a new naevus in adulthood or asymmetric growth is generally cause 
for suspicion and should be considered as a de novo melanoma until proven otherwise.196-198 
ϲ͘Ϯ͘ϱ͘ ŝŽƉƐǇ
Small lesions without su'cient clinical evidence for malignancy are either observed for 
growth and, particularly, growth rates or, if su'ciently conspicuous, are biopsied before 
being de"ned and treated as melanomas.199,200 !e biopsies today are performed more 
frequently for prognostic rather than diagnostic purposes.201-205 Routine use of cyto- or 
histologic con"rmation for diagnosis is not a current practice, unlike in a majority of 
other cancers, because of an over 95% accuracy rate of non-invasive diagnosis, at least for 
tumours thicker than 3.0–4.0 mm,17,108,161,206,207 whereas, as high as one-third of small CMs 
are initially misdiagnosed clinically.208 Despite the claimed risk for tumour dissemination 
secondary to diagnostic invasive approaches,200 a biopsy has been shown to be su'ciently 
safe and successful for tumours as thin as 0.7–1.0 mm209-211 and 2–3 mm149,209,212-215 in LBD. 
However, a "ne-needle aspiration or vitreous cutter biopsy does not exclude the possibility 
of a malignant tumour, including with a non-malignant result, because the sample might 
not be representative of the entire tumour, particularly of those that are transformed 
naevi.208,216,217 Conversely, a prognostic biopsy may occasionally return a wrong result.218,219 




In the TNM classi"cation, the anatomical extent of the primary tumour is marked with 
a T category. Its regional lymph node involvement, which is extremely rare with UMs,220-
222 is represented under the N, and eventual metastases with the M. Patients with evident 
regional lymph node or systemic metastases, irrespective of the tumour size, are staged as 
a stage IV. Ten-year Kaplan-Meier survival estimates for small CMs without ciliary body 
involvement or an extraocular extension (T1, stage I) range between 88–94% (95% CI, 
84–96%) and around 80% (95% CI, 75–84%) for medium sized (T2, stage IIA) CMs.24,223
Table 2. Current TNM stages of choroidal and ciliary body melanomas according to American 
Joint Committee on Cancer (AJCC)




































!ree main cell categories are microscopically distinguished in UM: spindle cell, epithelioid 
cell, and mixed.224 Spindle cell melanomas are associated with a better prognosis, mixed 
cell melanomas are associated with an intermediate prognosis, while epithelioid tumours 
grow faster, are more likely to metastasize, and are correlated with a shorter survival 
time.140,225-229 !e 15-year mortality rates of patients with spindle, mixed, or epithelioid cell 
melanoma are 19–26%, 59–60%, and 72–75%, respectively.230,231 An increase in the number 
of mitoses per 40 HPF, a high fraction of PC-10 and Ki-67 indicating high cellular activity, 
a large mean diameter of the 10 largest nucleoli,232-234 a high microvascular density,232,235 an 
increased in"ltration by lymphocytes236 and macrophages237,238, high expression of insulin-
like growth factor-1 receptor,239 a high expression of human leukocyte antigen I and II240, 
and the presence of extravascular matrix network patterns loops and networks241-243 have 
been associated with a worse prognosis.224,225,242,244-247
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ϲ͘ϯ͘ϯ͘ ǇƚŽŐĞŶĞƚŝĐƉƌŽŐŶŽƐƚŝĐĂƚŽƌƐ
!e better prognosis of patients with small CMs compared to those with large CMs is 
likely related to fewer and less risky cytogenetic abnormalities of small CMs compared to 
larger tumors and, hence, a lower metastatic capacity.4,103 UM carries distinctive molecular 
pathway defects, with its own chromosomal and molecular alterations.248-250 Prognostic 
biopsies of conservatively treated UMs that allow for the analysis of their cytogenetic, gene 
expression, and molecular genetic features are not yet a routine part of the treatment of all 
UM patients, but are increasingly more common.
A complete or partial loss of chromosome 3, which occurs in approximately 50% of UMs, is 
associated with a reduction of 50% in survival.251-256 !is loss of chromosome 3 is generally 
associated with a multiplication of chromosome 8, 8q, or parts of 8q, and additional copies 
of chromosome 8q are correlated with a high mortality rate.251,252 Monosomy 3 together 
with gains in chromosome 8q is thus associated with the highest risk for metastasis, whereas 
either monosomy 3 or gains in chromosome 8q are associated with an intermediate risk 
and disomy 3 with the lowest risk.214,252,257,258 Chromosome 1 and chromosome 6 changes are 
frequent as well.259-261 Loss of chromosome 1p correlates with a reduced survival rate,262,263 
whereas a chromosome 6p gain is suggestive of a protective e#ect and associated with a 
better prognosis.264 !e determination of the chromosomal status may be a#ected by prior 
irradiation.265 
Several somatic mutations have been identi"ed as having an in$uence on an UM patient’s 
prognosis. Tumorigenesis is driven by mutually exclusive gain-of-function mutations in 
members of the Gq signalling pathway (GNAQ, GNA11, PLCB4, or CYSLTR2) followed by 
near-mutually exclusive mutations in BAP1, EIF1AX, SF3B1, or SRSF2.266-268
GNAQ and GNA11 mutations, members of the q class of the G-protein (-subunits, 
are found in all stages of UM, but additionally found in naevi.85,88 !ree times as many 
metastatic UMs carry mutations in GNA11 as compared to GNAQ, suggesting that cells 
carrying a GNA11 mutation are designated for the metastatic process.83,84,269,270 Furthermore, 
PLCB4 and CYSLTR2 oncogenes are, similarly, a gain-of-function mutations leading to an 
activation of the same signalling pathway and thus promoting UM tumorigenesis.271,272
BAP1 has been mapped on a tumour suppressor gene located on chromosome 3, and its loss 
is a strong indicator for worse prognosis.82,115,269,273 Whole-exome sequencing of metastatic 
UMs has identi"ed inactivating somatic mutations in BAP1 in 84% of metastasizing 
tumours, suggesting that the inactivation of BAP1 is a pivotal event in the development 
of metastases.82 Mutations of the X-linked translation initiation factor EIF1AX have 
a protective e#ect and are associated with an 8-fold decreased risk of metastasis.87,269 
Similarly, mutations in the splicing factor SF3B1 are correlated with improved survival 
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rates as well,86,87,274 although there have additionally been studies that have concluded the 
opposite argument for this association.87,269
GEP is a technique which uses the mRNA of tumour biopsies in order to predict metastatic 
risk.254,275 Based on the results of their GEPs, UMs are divided into two major prognostic 
subgroups: those in the class 1 with a low (class 1A) or intermediate metastatic risk (class 
1B) and those in class 2 with a high risk.114,203,254,276 Class 1 tumours are associated with 
disomy 3, and the gain of 6p, and class 2 tumours are associated with monosomy 3 and 
mutations in the BAP1.82-85,88,114,271,272 Metastatic rates have been reported to be as low as 1% 
in class 1 and up to 26% in class 2 cases at a median follow-up time of 17 months.203 Patients 
with a class 2 UM tend to be older, have thicker tumours with epithelioid cells as well as 
a high mitotic rates, and present BAP1 mutations.203 Although the majority of metastases 
occur in patients with class 2 tumours, class 1 tumours may give rise to metastasis as well.203 
Preferentially expressed antigen in melanoma (PRAME) is an independent prognostic 




A majority of CMs are conservatively managed with radiotherapy, although selected large 
tumours continue to be treated with enucleation8,278,279 and certain  tumours undergo local 
resection280,281. Conservative treatment of CM aims to destroy the tumour while preserving 
as much useful vision as possible.
!ree major radiotherapeutic techniques are available: brachytherapy with various isotopes 
and radioactive plaques, external beam radiotherapy with photons from linear accelerators 
or gamma knives, and charged particle beams.282-289 All of these tehniques are e#ective for 
CMs of all sizes and have high rates of local control with survival rates that are similar 
to those observed a&er enucleation.72,290,291 TTT can be a safe method for selected patients 




Treatment with a beta emitter Ru106 applicator was "rst introduced in 1964 in former East 
Germany.45,293,294 It gradually became more popular, particularly within Europe in the 1970s 
to 1980s.295-302 Ruthenium106, with a half-life of 373.59 days, is suitable for CMs of up to 
5.4 mm in thickness because the beta radiation has a limited depth of penetration.9,303 !e 
advantage of Ru106 over gamma emitters and proton beam when treating small CMs is 
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thought to be fewer radiation-related complications and thus better preservation of vision 
since it causes less damage to healthy tissue.287,304,305
ϲ͘ϰ͘Ϯ͘Ϯ͘ZĂĚŝŽĂĐƟǀĞĂƉƉůŝĐĂƚŽƌƐ
Round episcleral plaques are bowl-shaped and 10–25 mm in diameter (Fig. 2).9 Notched 
plaques are available for juxtapapillary tumours and ciliary body tumours. Ruthenium106 
plaques are commercially manufactured as pure silver plaques with encapsulated 
radioactive Ru106. !eir outer surface is lined by a thick silver layer that absorbs more than 
99% of the radiation to prevent irradiation of tissues surrounding the eye,306 whereas the 
silver layer of the active inner side has a thickness of 0.1 mm. Eyelets allow the plaque to be 
sutured to the sclera. !e activity of the Ru106 plaque depends on the size and shape of the 
plaque and ranges between 4.1–40.3 MBq, equal to 0.11–1.09mCi.9
!e radiation dose is delivered to the tumour 
during a precalculated and continuous time 
period. !e planned dose and treatment period are 
directly proportional to the tumour thickness. !e 
prescription point is determined by the tumour 
thickness, to which 1 mm is added for the sclera. 
!e di#erence between the doses delivered to the sclera and apex increases with increasing 
tumour height. !e prescription dose to the apex is generally 80–120 Gy, and frequently 
aims to deliver at least 250 Gy to the sclera307, although certain centres prefer a scleral dose 
of 350Gy.308 Scleral doses as high as 1,500 Gy using Ru106 have been administered without 
scleral necrosis,309 which, however, remains a possible complication with such high doses.
!e conventional practice is to position the plaque centred over the tumour to ensure 
that it overlaps the tumour margins by at least 2 mm in all directions.6,282 !e notion of 
scattered irradiation has induced certain centres to use eccentric plaque placement, with 
the posterior edge of the plaque aligned with the posterior tumour margin and without 
a safety margin in an attempt to save the fovea and optic nerve.307,308,310 A wide radiation 
safety margin inevitably increases side-e#ects, particularly when the posterior tumour 
margin extends close to the optic disc or fovea.
ϲ͘ϰ͘Ϯ͘ϯ͘ ^ƵƌŐŝĐĂůƚĞĐŚŶŝƋƵĞ
Total or partial peritomy is performed to expose the underlying sclera, followed by a 
disinsertion of the muscles if the muscles are located in the tumour area in order to enable 
plaque positioning over the sclera. !e tumour margins are identi"ed, for example, by 
transilluminations or indirect ophthalmoscopy with indentation and are marked with 
diathermy or ink. For plaque positioning, a non-irradiating dummy plaque is used. Once 
it is placed correctly over the tumour, it is replaced with the radioactive plaque. Intra- and 
post-operative US can be useful to con"rm the exact plaque positioning.311,312 A mattrass 
Figure 2. Round radiation plaque 9
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suture over the plaque is recommended but is impossible when treating posterior tumours 
with the smallest plaques. !e plaque cannot be placed closer than approximately 1.5 
mm from the margin of the optic disc because of the optic nerve sheath, which has a 
diameter of 5.1 mm behind the eye.313 When the radioactive plaque is "xed to the sclera, 
any disinserted rectus muscles are resutured over the plaque, and the conjunctiva is closed. 
When the prescribed radiation dose has been delivered, the plaque is removed during a 
second procedure. Any disinserted rectus muscles are replaced in their anatomical position. 
!e inferior oblique muscle is generally le& unattached since it has frequently been only 
partially disinserted.
ϲ͘ϰ͘Ϯ͘ϰ͘ >ŽĐĂůƚƵŵŽƵƌƌĞĐƵƌƌĞŶĐĞ
Ru106 brachytherapy provides 5-year local recurrence rates from 2–15% for small and 
medium sized CMs when not restricted to a particular plaque size.303,307,314-317 A larger 
tumour size and posterior location are risk factors for recurrence.303,318 Although a majority 
of recurrences occur within the "rst few post-operative years, regrowth, including a&er 15 
years, has been reported.309 An increase in tumour size a&er initial tumour regression may 
occasionally further result from an intratumoural haemorrhage and does not necessarily 
indicate a local recurrence.319
ϲ͘ϰ͘Ϯ͘ϱ͘ KĐƵůĂƌƐŝĚĞͲĞīĞĐƚƐŽĨƌĂĚŝŽƚŚĞƌĂƉǇ
CMs are resistant to radiation, and their treatment, therefore, requires high radiation doses 
that may result in radiation-related complications and impaired best corrected visual acuity 
(BCVA). Brachytherapy of small posterior CMs with Ru106 leads to posterior segment 
complications such as radiation maculopathy, retinopathy and optic neuropathy, as well as 
vitreous haemorrhage, whereas anterior segment complications such as cataract and iris 
neovascularization, with or without neovascular glaucoma, are rare.308,309,317,320-323
Radiation maculopathy appears clinically as retinal vascular changes such as 
microaneurysms, telangiectasias, retinal haemorrhages, microinfarcts, macular oedema, 
neovascularization, and lipid exudation.31,324,325 Diabetic patients are at a higher risk.326 
Bevacizumab and intravitreal or periocular triamcinolone can transiently reduce macular 
oedema to maintain visual acuity (VA).311,327 Maculopathy caused by exudates and oedema 
can be treated by administering TTT to the tumour if the tumor is located outside the 
macula. !e 5-year cumulative incidence rate of developing radiation maculopathy 
following Ru106 brachytherapy is 30–55%.302,308,310,328
Radiation optic neuropathy is a less common complication a&er treatment of small 
posterior tumours with Ru106, presenting in up to 12% of cases a&er 5 years.302 !is risk 
is related to the distance of the posterior tumour margin to the optic disc and is minimal 
beyond 4 mm.328,329 
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ϲ͘ϰ͘Ϯ͘ϲ͘ sŝƐŝŽŶŽƵƚĐŽŵĞ
Radiation retinopathy and maculopathy continue to be vision-limiting complications 
following radiation exposure.330 Ru106 brachytherapy may allow to for the retaining of useful 
vision for a considerable period of time.300 Risk factors for losing vision a&er brachytherapy 
are older age, a lower initial BCVA, a tumour location close to the fovea or optic disc, a 
larger tumour thickness, and a temporal tumour location.307,309 !ree to 5 years a&er 
brachytherapy, approximately 50% of patients maintain a BCVA of 20/200 (decimal scale, 
0.1) or better, and 30% a BCVA of 20/50 (decimal scale, 0.4) or better in the tumour eye.309,331 
When using eccentric placement, up to 75 % of patients with their posterior tumour edge 
at least 3 mm from the fovea may retain 20/40 (decimal scale, 0.5) BCVA at 4 years a&er 
brachytherapy.308,310 Vision can further improve a&er radiation due to a resolution of SRF 
following tumour regression.57-59,332,333
When compared with Pd103, Ru106 brachytherapy is associated with improved preservation 
of vision.287 Following I125 brachytherapy, a good local tumour control of approximately 90% 
at 10-years has been achieved for small CMs, but the risk for a BCVA loss of 3 Snellen lines 
or more or deterioration of BCVA to less than 20/200 (decimal scale, 0.1) is approximately 
50% at 10 years.334 With proton beam radiation therapy, a nearly 100% local tumour control 
and satisfying long-term visual outcomes for tumours located further than 3 mm from 
the fovea and optic disc have been achieved a&er treatment of small tumours.335,336 !e 
probability of patients retaining BCVA of 20/200 or better was approximately 50% at 10 
years.335
ϲ͘ϰ͘ϯ͘ dƌĂŶƐƉƵƉŝůůĂƌǇƚŚĞƌŵŽƚŚĞƌĂƉǇ
TTT was introduced in the Netherlands as a treatment modality for CMs in 1995.48,337,338 
It was initially described in combination with Ru106 brachytherapy in an attempt to avoid 
radiation-related complications and preserve BCVA by reducing the radiation dose.48-50,339 
However, the reduction in loss of BCVA proved to be insigni"cant compared to treatment 
with Ru106 alone.314,340 TTT is now additionally used as a primary therapy or adjuvant 
therapy a&er brachytherapy.307 
In TTT, a diode laser beam is directed through the dilated pupil to the apex of the tumour 
for approximately one minute, resulting in an increase in the tumour temperature to 
45-60°C. !e consequence of this heating is a tumour necrosis to a maximum depth of 
4 mm,337,338 which is therefore considered to be the size limit for the indication of TTT 
as a primary treatment.48,57,338,341-343 Tumour regression continues for months and leaves an 
atrophic chorioretinal scar. !e importance of aiming for a completely $at tumour scar is 
to reduce the risk of a local recurrence, although recurrent tumours have been reported to 
arise from completely $at scars.55,56,333,344
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When a tumour is small and thin, TTT may be considered as a primary treatment provided 
that the patient accepts that such treatment may need to be followed by radiotherapy in 
cases of recurrent or persistent tumours.53 TTT causes an immediate local scotoma in the 
visual "eld, and delayed e#ects include macular scarring, epiretinal membranes, retinal 
vascular occlusions, and vitreous haemorrhages.292,342,344
High local recurrence rates, up to 45%52-60 have been a concern following TTT. Several 
studies have reported higher recurrence rates for parapapillary tumours compared to non-
parapapillary lesions.57,59,337,342,345 !e overlying retina undergoes atrophy, but the underlying 
sclera is resistant to hyperthermia.338 Consequently, TTT may be associated with intra- and 
extra-scleral recurrences, which are rare a&er brachytherapy.52,53 
ϲ͘ϰ͘ϰ͘ WƌŽƚŽŶďĞĂŵƚŚĞƌĂƉǇ
One option for radiotherapy is external beam radiation using charged particles such 
as protons283 despite facilities for proton beam only being available in a limited number 
of centres around the world. !is technique allows for a uniform dose distribution to a 
circumscribed target volume including the tumour, resulting in improved local tumour 
control and less damage to healthy tissues.346 Proton beam therapy is generally preferred for 
larger tumours that are not eligible for brachytherapy or for posteriorly located tumours, in 
an attempt to spare the macula and optic disc.347
Local tumour recurrence rates for CM of patients with tumours of all sizes have been 
reported at approximately 4% at 5 years347 and 5% at 10 years.348 !e local recurrence rate 
was 5% at 15 years for tumours with a median of 5.3 mm in thickness and 13.2 mm in 
LBD.349 For T1 tumours, no recurrences were observed during a mean follow-up of 10 
years.335
BCVA outcomes following proton beam therapy depend on tumour thickness and 
proximity to the fovea and optic disc.335,350 Patients with a tumour located at least 3 mm 
from these posterior structures generally do not develop clinically signi"cant radiation 
vasculopathy.351 !e risk for visual loss at 5 years has been estimated at 68% for small and 
medium-sized tumours.352 Five-year cumulative rates of maculopathy and papillopathy 
were 64% and 35 % when the analysis was restricted to a group of patients with small- to 
moderate-sized tumours located within 4 disc diameters of the optic nerve or macula.352 
!e frequency of losing BCVA of 20/200 for tumours located further than 3 mm from fovea 
and optic disc was approximately 7% at 5 years, and 18% at 10 years.335 !e corresponding 
rates for tumours located closer than 3 mm from the posterior structures was approximately 
40%% at 5 years and 53% at 10 years.
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ϲ͘ϱ͘ϱ͘ ǆƉĞƌŝŵĞŶƚĂůƚƌĞĂƚŵĞŶƚƐ
Photodynamic therapy (PDT) with vertepor"n was originally used for choroidal 
neovascularization in age-related macular degeneration.353 It has been reported that PDT 
induces tumour regression for 62% to 100% of treated small posterior CMs,354,355 resulting 
in treatment outcomes that are less reliable with regard to tumour regression compared to 
other treatment modalities356 but without the associated decrease in BCVA.355,357 Although 
PDT has been reported to be e#ective in both amelanotic and pigmented tumours,358 doubts 
have been raised concerning its e'cacy in treating the pigmented tumours.359,360 PDT was 
additionally reported to be more e#ective for treating tumours with three or fewer risk 
features for growth.354
AU-011 is a novel virus-like particle-drug conjugate that selectively binds to cancer cells 
and enables a targeted therapy for UM.361,362 !e drug is administered through intravitreal 
injection and subsequently activated with an infrared laser, which leads to targeted tumour 
cell necrosis while simultaneously sparing healthy tissue.363 Preliminary results support the 
further development of this modality.364
ϲ͘ϲ͘ Dd^d^/^E^hZs/s>
Metastatic UM is the leading cause of death in UM patients, with the mortality rate 
being higher than 50% a&er 25 years of primary treatment for medium-sized and large 
tumours.20,92,365,366 Small tumours have a much better prognosis, with a metastatic rate of 
approximately 12% in 10 years.24 It is not known exactly when dissemination takes place. 
Clinically evident metastases are detected in less than 1–3 % of all patients at the time of 
UM diagnosis, and the median length of time until detection of metastasis is 2 years a&er 
treatment for UM in general.92,367 It has been estimated that tumours may have the capacity 
to disseminate years before the diagnosis of the primary tumour.190,368 Studies of tumour 
doubling times of metastatic lesions have suggested that metastasis may commence when 
the primary tumour continues to be small, that is approximately 3 mm in LBD and 1.5 
mm in thickness.193 !e smallest CMs that have been reported to metastasize have been at 
least 1.7 mm thick369 and 5.0 mm in LBD156,292,369-375. Growth of metastases may be delayed, 
and metastases may appear clinically up to three decades a&er successful treatment of the 
primary tumour due to a slow growth pattern and later cytogenetic progression.20,92,190
UM has a predilection to metastasize to the liver in over 90% of cases.19,376,377 Liver is the 
only site in 33–56% of metastatic patients.5,92,366,376,378 Other less common, and generally 
secondary, sites are the lungs, subcutaneous tissue, bones, brain, adrenal glands, and the 
heart.19,376,379-381 Metastases are more widespread than clinically suspected in patients who 
undergo autopsy.366 Symptoms vary, depending on the a#ected organ; yet, more than 60% 
of patients are asymptomatic when their metastases are detected.382 
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When a six-monthly screening protocol is applied, metastases are detected before the onset 
of symptoms in more than 90% of UM patients.383 Di#erent protocols have been reported, 
but a majority of UM patients are checked for liver metastases every 6 or 12 months, 
depending on their tumour stage, using imaging techniques such as abdominal US, MRI, 
and liver function tests (LFTs).382-385 New abnormalities in the LFTs or appearance of the 
liver are highly suggestive of metastasis. However, LFTs can be normal in approximately 
one-third of cases with liver metastasis.382 Abdominal US combined with LFTs is a sensitive 
screening modality, particularly when followed by a con"rmatory MRI in cases of newly 
detected lesions.386 A histopathological con"rmation of suspected metastases is performed 
if possible – and certainly when active treatmen is to be proposed – depending on the 
general condition of the patient.
In the presence of metastases, survival prognosis is poor as no curative treatment is 
generally available at the moment. !e median survival of patients with metastatic 
UM ranges from 6 to 13 months.23,367,387,388 !e death rate following clinically diagnosed 
dissemination is 80% at 1 year and 92% at 2 years, and a long-term survival time of more 
than 5 years is exceptional.19,389-391 Systemic treatment can only slow metastatic growth and 
improve survival to a limited extent.5,388 
Although there are many therapeutic options, there is no established standard of care 
for patients with metastatic disease. !ese options include systemic and intrahepatic 
chemotherapy, transarterial chemoembolization, isolated hepatic perfusion, protein kinase 
inhibitors, selective internal radiation therapy, immunoembolization, immunosuppressants, 
partial hepatectomy, microwave ablation, selective internal radiotherapy, and liver-directed 
thermotherapy.23,389 With a local resection of solitary liver metastases, a survival of seven 
years has been reported, but this is only available for a minimal number of selected 
patients.392-395 Patients with a loss-of-function mutation in the MBD4 gene are likely 
to bene"t from CPI immunotherapy, a group of agents successfully used in cutaneous 
melanoma therapy.118,130-132
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ϳ͘ ŝŵƐŽĨƚŚĞƐƚƵĚǇ
!e "rst two studies (Study I and II) in this thesis analysed the treatment results of small 
CMs of less than 10 mm in LBD with the 10-mm Ru106 plaque. !e second study compared 
these results with those of similarly sized melanomas treated with the 15-mm Ru106 plaques. 
!e third study (Study III) reported sizes and clinical features of the smallest CMs that 
metastasized. !e fourth study (Study IV) reported the growth rates and doubling times of 
presumed incipient CMs.
!e speci"c aims of this study were as follows:
I. To assess local tumour control, side-e#ects, and BCVA in a population-based 
consecutive series of patients who received brachytherapy for CM less than 10 mm 
in LBD with the 10-mm Ru106 plaque.
II. To assess local tumour control, side-e#ects, and BCVA in a population-based 
consecutive series of patients who received brachytherapy for CM less than 10 mm 
in LBD with the 10-mm or 15-mm Ru106 plaque and compare the outcomes between 
two groups.
III. To empirically determine the size limit at which a small CM acquires the capacity to 
metastasize and to assess the clinical characteristics of small fatal CMs
IV. To analyse tumour doubling times and growth rates as potential alternative 
diagnostic criteria for incipient small CMs in a population-based study with a 
consecutive series of patients with presumed incipient CM that was subsequently 
managed with primary TTT





Patients who were clinically diagnosed with a CM less than 10 mm in LBD and managed 
with primary brachytherapy with the 10-mm (Study I and II) or a 15-mm (Study II) Ru106 
plaque were eligible to participate in these studies. A patient was ineligible if the tumour 
involved the ciliary body or iris. !e database of the Ocular Oncology Service, Department 
of Ophthalmology, Helsinki University Hospital, a national referral centre for UM patients, 
was reviewed. 
!e time period for Study I began in October 1998 – at which point the 10-mm plaque 
became a treatment of choice in Helsinki University Hospital – and ended in December 
2010, with follow-up data being collected until the end of 2011. Within this time period, a 
total of 118 patients with an UM less than 10 mm in LBD were identi"ed, of whom, 48 were 
treated with the 10-mm plaque. !ree patients had a ciliary body or iris tumour, resulting 
in 45 patients being enrolled. 
!e time period of Study II began in October 1998 as well. Patients were treated with the 
10-mm or 15-mm plaque until December 2014, and follow-up data were collected until the 
end of 2017. Within this period, a total of 234 patients with CMs less than 10 mm in LBD 
were identi"ed, of whom, 76 were scheduled for treatment with the 10-mm and 88 were 
scheduled with the 15-mm plaque.
ϴ͘ϭ͘Ϯ͘ ^ƚƵĚǇ///
Data on consecutive patients diagnosed with a CM of 3 mm or less in thickness and 9 mm 
or less in LBD who subsequently developed metastases were collected from 10 ophthalmic 
oncology centres in Europe that agreed to participate in the study, including 9 patients 
from the Ocular Oncology Service, Department of Ophthalmology, Helsinki University 
Hospital. !e data of 56 patients were collected, of whom, 11 were excluded a&er an 
eligibility check and 45 enrolled. Excluded were 5 patients who had tumours larger than the 
eligibility criteria, 3 patients who had incomplete key data, one patient who was diagnosed 
with pulmonary metastases from an epithelioid cell melanoma, and 2 patients who had 
only extrahepatic metastases without histopathological veri"cation. !e patientes had been 
were diagnosed with CM between 1962 and 2010.
ϴ͘ϭ͘ϯ͘ ^ƚƵĚǇ/s
All 9 consecutive patients who had been diagnosed with a presumed incipient CM following 
documented growth and subsequently treated with primary TTT between 2010 and 2017 in 
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the Ocular Oncology Service, Department of Ophthalmology, Helsinki University Hospital 
were eligible for this retrospective study. One of the patients had a previous T2aN0M0, 
Stage IIA, CM in the same eye that had been treated with the 15-mm ruthenium plaque 2.5 
years before the second tumour (enrolled in the present study) was diagnosed.
ϴ͘Ϯ͘ WZ/DZzdZdDEd
ϴ͘Ϯ͘ϭ͘ ƌĂĐŚǇƚŚĞƌĂƉǇ;^ƚƵĚŝĞƐ/ĂŶĚ//Ϳ
!e treatments were performed by three experienced ocular oncologists over the 16-year 
period. !e prescription point was tumour thickness plus 1 mm for the sclera. Treatment 
times and doses were calculated from the central axis depth dose curve. !e standard 
prescription dose was either 100 Gy or 120 Gy to the apex depending on the thickness 
of the tumour and aimed to deliver a minimum dose of 250 Gy to the sclera. Overlying 
extraocular muscles were disinserted if needed to ensure accurate positioning of the plaque 
in relation to the tumour. 
!e cord diameter of the radiation window of the plaque in spherical form is 9.4 mm 
and 12.9 for 10-mm and 15-mm plaques, respectively (Eckert & Ziegler BEBIG GmbH, 
Berlin, Germany). !e radiation window is surrounded by a 0.75-mm-wide inactive 
border. !e radiation window is surrounded by a penumbra of scatter radiation, which is 
used as justi"cation for eccentric plaque placement in order to limit irradiation to adjacent 
tissues.310,396 Plaque position and distance to the tumour apex were veri"ed on the "rst 
postoperative day with US in view of a calculation update of the treatment time. However, 
this practice was not in use in the early study years.
ϴ͘Ϯ͘Ϯ͘ dƌĂŶƐƉƵƉŝůůĂƌǇƚŚĞƌŵŽƚŚĞƌĂƉǇ;^ƚƵĚǇ/sͿ
TTT was delivered through a dilated pupil in periocular anaesthesia with an infrared diode 
laser (MedArt 426, MedArt, Hvidovre, Denmark) at a wavelength of 810 nm which was 
adapted to a slit lamp biomicroscope and which used beam diameters of 0.8 to 3.0 mm and 
a contact lens (Area Centralis or Quadraspheric, Volk Optical, Mentor, OH). !e spot was 
applied 1 to 4 times with increasing power if needed (median, 1,500 mW; range, 700–3500) 
for a median duration of 120 s (60–285) to achieve a greyish white colour on the surface of 
the tumour. Overlapping spots, if needed, were used to cover the entire tumour, and there 
was a margin of 0.5 to 1.0 mm on all sides. TTT was repeated 1 to 5 times at intervals of 







!e tumour size was primarily determined by indirect ophthalmoscopy and B-scan US. 
Biomicroscopy and indirect ophthalmoscopy were used to localize the tumour margins 
in order to measure the distance from the posterior tumour margin to the optic disc 
and foveola and evaluate the presence of SRF and OP. Patients were treated if they had a 
presumed small CM that either had been observed to grow or had high-risk features for 
growth27,42,397 (Tables 3–4). !e BCVA was measured using a test-type projector (Rodavist 
2 and 524; Rodenstock GmbH, Ottobrunn, Germany) in even decimal steps from 20/20 
(decimal scale, 1.0) to 20/200 (decimal scale, 0.1) plus 20/400 (decimal scale, 0.05). A 
BCVA worse than 20/400 was recorded as counting "ngers at 2 m, 1 m, and 0.5 m; hand 
movement; light perception; and no light perception.
Table 3. Risk factors for growth27,42 in 45 (Study I) and 164 (Study II) patients with small 
choroidal melanomas less than 10 mm in largest basal diameter, of whom 76 were managed 
with the 10-mm plaque and 88 with the 15-mm plaque (Studies I and II). Study I patients are 
included in Study II.
      KďƐĞƌǀĞĚ'ƌŽǁƚŚ͕Ŷ;йͿ
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ZŝƐŬ&ĂĐƚŽƌƐ Ŷсϰϱ Ŷсϳϲ Ŷсϴϴ WΎ Ŷсϭϴ ŶсϮϵ ŶсϯϮ WΎ
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Table 4. Number of risk factors42 for growth in 45 (Study I) and 164 (Study II) patients with 
small choroidal melanoma less than 10 mm in largest basal diameter who were treated with the 
10-mm and the 15-mm ruthenium106 plaque. Study I patients are included in Study II.
  ^ƚƵĚǇ/ ^ƚƵĚǇ//͕Ŷ;йͿ
  Ŷ;йͿ ͲͲͲͲͲͲͲͲͲͲͲͲͲͲͲͲͲͲͲͲͲͲͲͲͲͲͲͲͲ
EƵŵďĞƌŽĨ ϭϬͲŵŵ ϭϬͲŵŵ ϭϱͲŵŵ
ZŝƐŬ&ĂĐƚŽƌƐ Ŷсϰϱ Ŷсϳϲ Ŷсϴϴ WΎ
Ϭ  ϰ;ϵͿ ϵ;ϭϮͿ ϱ;ϲͿ Ϭ͘ϭϮ
ϭ  ϱ;ϭϭͿ ϵ;ϭϮͿ ϭϬ;ϭϭͿ
Ϯ  ϵ;ϮϬͿ ϭϲ;ϮϭͿ ϭϳ;ϭϵͿ
ϯ  ϭϭ;ϮϰͿ ϭϰ;ϭϴͿ ϯϬ;ϯϰͿ
ϰ  ϭϭ;ϮϰͿ ϭϵ;ϮϱͿ Ϯϭ;ϮϰͿ
ϱ  ϱ;ϭϭͿ ϵ;ϭϮͿ ϱ;ϲͿ
*non-parametric test for trend
In Study I, 4 (9%) patients who had none of the risk features were treated due to observed 
growth. In Study II, 14 patients had a tumour without risk features, of whom, 12 (7%) 
were treated because of observed growth, one had a tumour that had not been seen during 
regular glaucoma follow-up, and one had a ruptured Bruch’s membrane.
ϴ͘ϯ͘ϭ͘Ϯ͘ ^ƚƵĚǇ///
!is retrospective study was conducted using patient charts, archival images, and pathology 
data. Members of the European Ophthalmic Oncology Group submitted anonymous data 
from 10 ocular oncology services to a secure survey website. !e data requested included 
date of birth, diagnosis, primary treatment, local recurrence, and diagnosis of metastases as 
well as sex, ethnicity, involved eye, BCVA, history of a previous naevus, high-risk features 
for growth and metastasis,27,42 observation before treatment, type of the primary treatment, 
histopathologic diagnosis, secondary treatments, systemic treatment, and last status.
ϴ͘ϯ͘ϭ͘ϯ͘ ^ƚƵĚǇ/s
Digital fundus images were used to localize the tumour margins in order to estimate the 
distance from the posterior tumour margin to the optic disc and foveola and to evaluate 
its growth as well as the presence of SRF and OP. Based on OCT, a tumour was considered 
$at if the tumour area was not elevated compared to the adjacent normal choroid. !e 
BCVA was measured using a test-type projector (Rodavist 2 and 524; Rodenstock GmbH, 
Ottobrunn, Germany) in even decimals from 1.0 (20/20) to 0.1 (20/200). 
Diagnosis was based on veri"ed tumour growth relative to the age of the patient and 
reported chance of having a growing choroidal nevus, TDT, growth rate, and to the 
calculated age of tumour origin. Patients were selected to have primary TTT instead of 
brachytherapy due to the small tumour sizes.
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!e initial data were collected from the medical records of each patient, including details on 
age, race, gender, diabetes, ocular history, tumour growth, high-risk factors, BCVA, tumour 
location, tumour measurements, and information from TTT. Data a&er completion of TTT 
included "nal BCVA, tumour control, TTT complications, and last status.
ϴ͘ϯ͘Ϯ͘ ĂůĐƵůĂƚŝŽŶƐŽĨŐƌŽǁƚŚƌĂƚĞƐĂŶĚĚŽƵďůŝŶŐƚŝŵĞƐ
For this study, the tumour growth rate was calculated starting from its LBD and using a 
theoretical measure of 0.05 mm when the tumour was not visible in the "rst photograph. 
!e tumour volume was then estimated presuming a cylindrical form because all tumours 
were assumed to have the same thickness as the choroid since the tumours did not thicken 
the adjacent choroid on the OCT images. !e surface area of the tumour was calculated 
by using ImageJ so&ware (National Institute of Health, Maryland, USA, Version 1.51). 
Two investigators measured the tumour area independently by two di#erent methods 
(manual drawing and automatic recognition of tumour margins) and the "nal area that was 
taken was the mean of these four measurements. !e date of the diagnosis of the primary 
tumour was the day on which an ophthalmologist "rst made the diagnosis of CM due to 
veri"ed growth. !e date of "rst observation was the date when the lesion had been "rst 
documented. Observation time (T) was the di#erence between these two dates.
TDT was calculated according to Schwartz398:
where T = observation time, Vdg = tumour volume at diagnosis, and Vini = initial tumour 
volume.
!e predicted initial age was additionally calculated to estimate whether the tumours 
had originated in adulthood and thus, were likely to be de novo tumours (equation 2).  A 
theoretical initial LBD of 0.05 mm was used when a tumour likely would have been visible.
where Agepred = age when the tumour was predicted to be visible, Ageini = age when the 
tumour was initially observed, TDT = tumour doubling time (equation 1), Vini = initial 
tumour volume, and Vorig = theoretical volume 0.000125 mm3 based on 0.05 mm diameter. 
Calculations were based on a presumed constant exponential growth.399
For comparison, TDTs collected for 196 patients with a UM reported in 4 articles to serve as 
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   (equation 2) 
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UM TDT was 521 days (range, 10–8766). !e reported median growth rate for choroidal 
naevi, that is 0.04 mm/year (range, 0.01–0.2) and 1.1 %/y (range, 0.2–11.6), for 89 naevi 
that showed photographic evidence of enlargement43  – excluding a tumour that later had 
been diagnosed as a CM – was used as a counter reference.
ϴ͘ϯ͘ϯ͘ ƐƐĞƐƐŵĞŶƚŽĨŽƵƚĐŽŵĞƐ;^ƚƵĚŝĞƐ/ĂŶĚ//Ϳ
Patients were followed at 3, 6, and 12 months; then every 6 months until 3 to 4 years a&er 
brachytherapy, and annually therea&er. Biomicroscopy, indirect ophthalmoscopy, fundus 
photography, and B-scan echography (I3 System-ABD; Innovative Imaging, Sacramento, 
California) were used to assess tumour control. Recurrences were coded as being vertical, 
marginal, di#use, or extrascleral.402
!e location of the plaque was retrospectively modelled in relation to the tumour to 
facilitate determining the reasons for a local recurrence. !e location of the plaque was 
coded as ‘covering the entire tumour with a safety margin’ (covered), as ‘being parallel’ 
(eccentric), or as ‘not covering the entire tumour’ (not covered). A circle was digitally drawn 
to the post-treatment photographs, that corresponded in size to the radiation window. !is 
was done using radiation and diathermy scars, with the presumption that the diameter of 
the optic disc was 1.5 mm.
Complications were assessed, as outlined, in a previous study on brachytherapy from 
the same ocular oncology service.403 Radiation maculopathy was diagnosed based on the 
appearance of retinal haemorrhage, mircoaneurysms, microinfarcts, oedema, exudation, 
and a decrease in BCVA. A tumour recurrence involving the fovea, scarring, or a macular 
pucker were categorized as ‘maculopathy for other reasons’. Optic neuropathy was 
categorized as radiation optic neuropathy based on the appearance of oedema, peripapillary 
splinter haemorrhages, or microinfarcts. 
ϴ͘ϯ͘ϰ͘ ƐƐĞƐƐŵĞŶƚŽĨƐƵƌǀŝǀĂůĂŶĚŵĞƚĂƐƚĂƚŝĐƐƚĂƚƵƐ;^ƚƵĚŝĞƐ/ĂŶĚ//Ϳ
LFTs and upper abdominal US were performed at the time of diagnosis and annually 
therea&er, and a chest radiogram was performed only at diagnosis. Conspicuous "ndings 
of concern were veri"ed with CT or MRI and, eventually, histopathologically. Causes of 
deaths were veri"ed from death certi"cates obtained with permission from Statistics 
Finland, autopsy reports, and patient charts.
ϴ͘ϰ͘ ^dd/^d/>Dd,K^EdE>z^/^
Follow-up data were collected prospectively into a dedicated database (MS Access; 
Microso&, Seattle, WA) and analysed with Stata statistical so&ware (Release 10, 13 and 15; 
Stata Co, College Station, TX). A cumulative incidence analysis404 was used that accounted 
for competing events in order to analyse the time to individual complications and death 
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– except in the third study where the analysis of time to systemic metastasis and survival 
was based on the Kaplan-Meier product-limit method since, by de"nition, all patients 
developed systemic metastases and none died of other causes.
All tests were 2-tailed, and a P-value less than 0.05 was considered statistically signi"cant. 
!e data were summarized as frequencies and percentages for categorical variables and as 
a median with a range for continuous variables. A Fisher’s exact test was used to compare 
dichotomous variables. A non-parametric test for trend was used exploring the di#erences 
between two independent groups for ordinal variables. A Kruskal-Wallis test was used 
between two or more independent groups for continuous variables, and a Gray’s k-sample 
test405 was used to compare cumulative incidences between two groups. Parameters 
including the time to local recurrence, low vision (BCVA  20/65; decimal scale, 0.3), 
and blindness (BCVA  20/400; decimal scale, 0.05) were modelled by univariable and 







All tumours treated with the 10-mm plaque were classi"ed as T1aN0M0, stage I, by the 
AJCC TNM-System. Eighty-two percent of tumours treated with the 15-mm plaque were 
classi"ed as T1aN0M0, stage I, and the remaining tumours with a thickness over 3 mm and 
LBD over 9 mm were classi"ed as T2aN0M0, stage IIA (Fig. 3).145
!e melanomas of the patients treated with the 15-mm plaque were thicker as a group 
(median, 1.9 vs 2.6 mm, P<0.001), had larger LBDs (median, 7.1 vs 8.6, P<0.001) and longer 
distances from the posterior tumour margin to the center of the fovea (median, 2.0 vs 2.8, 
P<0.001) (Table 5, Fig. 3). In Study II, the median age at diagnosis (65 vs. 63 years; P=0.59), 
the median follow-up time for patients who were still alive (8.1 years, range 3.0–18.8 vs. 
8.9 years, range 1.1–17.9; P=0.67), and the median BCVA (20/25 vs. 20/30; P=0.54) were 
comparable between the two groups (Table 5).
Table 5. Baseline characteristics at the time of diagnosis of 45 (Study I) and 164 (Study II) 
patients with a small choroidal melanoma less than 10 mm in largest basal diameter irradiated 
with the 10-mm (Studies I and II) or the 15-mm (Study II) ruthenium106 plaque. Study I patients 
are included in Study II.
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Figure 3. 45 (Study I, red symbols) and 164 (Study II) small choroidal melanomas less than 10 
mm in largest basal diameter (LBD) irradiated with the 10-mm (circle, red and black) or the 
15-mm (square black) ruthenium106 plaques. A, Scatterplot of radiation dose to the sclera against 
dose to the tumour apex. Dashed lines indicate minimum prescription doses. B, Scatterplot 
of LBD against tumour height. Long and short dashed lines enclose tumours which ful"l the 
American Joint Committee for Cancer (AJCC) Tumour, Node, Metastasis (TNM, 8th Edition)145 
and the Collaborative Ocular Melanoma Study (COMS)31 criteria for a small UM, respectively. 
C, Scatterplot of proximity of tumour margin to the foveola against proximity to the optic disc. 
Dashed lines indicate a distance of 2 DD (3 mm) from these structures, frequently considered 
to be a safety margin for not developing radiation maculopathy and optic neuropathy from 





!e location of the plaque was assessed according to the surgical charts and by retrospective 
modelling (Table 6). In the comparative Study II, tumour coverage was statistically 
signi"cantly di#erent between the two groups (P=0.002) but di#ered to a lesser extent 
(P=0.052) a&er remodeling.
Table 6. Location of the plaque according to the surgical charts and by retrospective modelling 
of 45 (Study I) and 164 (Study II) patients with a small choroidal melanoma less than 10 mm 
in largest basal diameter irradiated with the 10-mm (Studies I and II) or the 15-mm (Study II) 
ruthenium106 plaque.
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A total of 4 patients developed a local recurrence in Study I. A local recurrence was detected 
in 9 and 16 patients treated with the 10-mm and the 15-mm plaque, respectively, in Study 
II. Recurrences were controlled with a secondary iodine plaque, except in three patients, of 
whom one had been retreated with a secondary Ru106 plaque and two had been treated with 
TTT. In Study II, the cumulative incidence of developing a local recurrence was comparable 
between the two groups (Table 7). By univariable Cox regression, a local recurrence was 
associated with an eccentric plaque location (HR 3.40 for a plaque not covering the tumour 
with a safety margin, P=0.024) (Table 6, Study II).
Of the 45 patients in Study I, 6 died during the follow-up. Five patients died for reasons 
other than metastatic disease, and one death was classi"ed as being the result of possible 
metastasis to the brain as the only site, although this had not been histopathologically 
veri"ed. Within the Study II period, a further 3 patients died of metastatic CM a&er a local 
tumour recurrence following treatment with the 10-mm plaque. Seven patients, of whom 4 
had experienced a local tumour recurrence, died of metastatic CM a&er treatment with the 
15-mm plaque. !e development of metastases, all-cause, and melanoma-related mortality 
rates were comparable (Table 7). !e time from treatment to metastases (median, 4.6 vs 4.5 
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years; P=0.85) and survival a&er diagnosis of metastases (median, 3.6 vs 6.1 years; P=0.73) 
were comparable between the two groups.
Table 7. Summary of outcomes using cumulative incidences a&er treatment of 164 patients with 
small choroidal melanomas less than 10 mm in largest basal diameter with the 10-mm or the 
15-mm ruthenium106 plaque
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Radiation maculopathy and optic neuropathy were the most frequent radiation- related 
complications. Radiation maculopathy was diagnosed in 14 eyes within the Study I period 
and in 17 and 20 eyes a&er treatment with the 10-mm and the 15-mm plaque in Study 
II, respectively. !e cumulative incidence of developing radiation maculopathy and 
maculopathy other than radiation maculopathy were comparable between the two groups 
in Study II (Table 7). Additionally, the distance of the tumour margin to the center of the 
foveola (median, 0.5 vs 1.0 mm, P=0.23) was comparable in eyes that developed radiation 
maculopathy.
One eye developed radiation optic neuropathy a&er treatment with the 10-mm plaque 
(Studies I and II) of a tumour located at 4 mm from the optic disc. Optic radiation 
neuropathy developed in 7 eyes a&er treatment with the 15-mm plaque. !e cumulative 
incidence rates of developing optic neuropathy (Table 7) and the distance of the posterior 





A tumour thickness of more than 3.0 mm was associated with more frequent loss of vision, 
particularly a&er treatment with the 10-mm plaque, although the number of patients with 
such a thick tumour was small. Instead, a location of the tumour margin at less than 1.5 
mm from the optic disc and foveola was a more prominent indicator for vision loss a&er 
treatment with the 15-mm plaque (Fig. 5, Study II). !e cumulative incidences of losing a 
minimum BCVA of 20/65 (low vision) and the development of blindness (BCVA  20/400) 
were comparable between the two groups (Table 7). 
By univariable Cox regression, low vision and blindness of the tumour eye were associated 
with a shorter distance to the foveola, a worse baseline BCVA, and larger tumour thickness. 
Of bivariable models using plaque size, the model including the distance to the foveola 
independently and best predicted low vision (HR, 0.64 for each 1 mm increase in distance, 
P<0.001; Table 8, Study II). Distance to the foveola was further associated with blindness in 




!e median thickness of a SFCM at the time of treatment was 2.4 mm (range, 1.0–3.0 mm, 
Table 8) and its median LBD was 7.3 mm (range, 3.0–9.0 mm). None of the 45 tumours 
was less than 3.0 mm in LBD at the time of treatment (Fig. 1, Study III), whereas 27% of 
the 45 tumours ranged from 3.0–6.0 mm and 73% from 6.1–9.0 mm in LBD. Risk factor 
frequencies (Table 8) at the time of diagnosis were similar to those reported in a study on 
35 small melanocytic choroidal tumours that metastasized27 (Table, Study III).
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Table 8. Baseline characteristics and outcomes of 45 patients with a small choroidal melanoma 









































BCVA = Best corrected visual acuity; DD = Disc diameter; Data are no. (%) unless otherwise 
indicated; *Median (range); † (Number of events/numbers at risk); ‡ the acoustic pro"le lower/




Local recurrence only occurred a&er conservative treatment. !e cumulative incidence of 
developing a local recurrence was 17% (95% CI, 7–29) by 5 years and 19% (95% CI, 9–32) 
by 10 years. By study design, all patients presented metastatic disease. !e cumulative 
incidence of developing metastasis was 51% (95% CI, 36–64) by 5 years and 85% (95% 
CI, 71–92) by 10 years a&er primary treatment. !e Kaplan-Meier estimate of melanoma-
related death following the detection of metastasis was 52% (95% CI, 37–66) at 1 year, 77% 
(95% CI, 60–88) at 2 years, and 84% (95% CI, 66–93) at 3 years.
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!e median age of the patients was 55 years (range, 41–77) when the tumour was "rst 
documented. All tumours were "rst detected in fundus photographs taken for various 
reasons (Supplemental text, Study IV). Two patients had fundus photos without a visible 
tumour. !e median tumour thickness was 0.20 (range, 0.15–0.29) mm on OCT. None 
of the tumours was thicker than the adjacent choroid. !e median LBD was 0.52 (range, 
0.05–1.09) mm. None of the tumours showed any risk features for malignancy when "rst 
documented.
ϵ͘ϯ͘Ϯ͘ dƵŵŽƵƌĐŚĂƌĂĐƚĞƌŝƐƚŝĐƐĂƚĚŝĂŐŶŽƐŝƐ
!e median time to observe tumour growth before its diagnosis as an incipient CM was 3.3 
years (range, 2.2–7.3 years), at a median age of 57 years (range, 47–78) (Fig. 4A). Tumour 
thickness was unchanged, but the LBD had increased to a median of 1.6 (range, 0.93–2.32) 
a&er this observation. All patients had a BCVA of 20/25 (decimal scale, 0.8) or better in the 
tumour eye, except one patient with a cataract who had a BCVA of 20/40 (decimal scale, 
0.5). !e median distance to the foveola was 3.7 mm (range, 0.5–5.3) and 2.3 mm (range, 
0-6.8) to the optic disc margin (Fig. 4B). !e posterior tumour margin touched the optic 
disc in one eye and extended to within 2 DD of the disc margin in six eyes. One patient had 
developed four risk features: symptoms, SRF, OP, and tumour margin touching the optic 
disc. Eight tumours grew symmetrically, including the 2 in the eyes in which a previously 
normal fundus had been documented. Two patients had a presumed previous nevus that 
started to grow, of whom one had an asymmetrically growing tumour.
!e median growth rate was 0.25 (range, 011–0.72) mm/y corresponding to 34 %/y, which 
was faster than the growth rate derived from the reference data of 88 growing naevi43, 
(P<0.001, Kruskal-Wallis test) they were compared with. Restricted to the 7 de novo 




!e tumour volume doubled at a median of 2.4 (range, 0.95–9.6) times. !e median TDT 
(Fig. 4A) of 609 days (range, 97–1612) for all tumours, and 393 days (range, 97–609) for 
de novo tumours was comparable with the reference data of 194 melanomas191,192,400,401 (P 
=0.62, Kruskal-Wallis test). 
Excluding the two likely transformed naevi, the predicted interval from the time when the 
tumour would have been invisible and the corresponding predicted theoretical patient age 
was 11.7 years (range, 0.6–34.6) and 51 years (range, 32–63), respectively.
Figure 4. Nine small choroidal melanomas treated with primary transpupillary thermotherapy. 
A, Scatterplot of observation time against tumour doubling time. B, Scatterplot of proximity 
of tumour margin to the foveola against proximity to the optic disc. Solid and open symbols 
indicate previous naevi and de novo melanomas, respectively. Red symbols indicate the tumour 




One to four (median, 1) TTT applications were applied. Based as well on OCT, the treatment 
outcome was a white scar with minor RPE remnants in 56% of the patients, a white scar 
with a focal reactive proliferation of the RPE in 33%, and, as a result of an RPE tear, a scar 
with prominent reactive RPE proliferations in 1 patient. !e median follow-up time a&er 
the last TTT session was 2.1 years (range, 7.5 months–8.7 years). None of the patients had 
developed a local tumour recurrence or metastases within the study period. !e BCVA 
was unchanged in all but two eyes. One patient with a tumour under the papillomacular 
bundle had a BCVA of 20/40 (decimal scale, 0.5) a&er completion of TTT. She developed 
a macular epiretinal membrane and underwent vitrectomy 8 years a&er TTT. !e second 
patient had a BCVA of 20/125 (decimal scale, 0.16) even a&er cataract surgery, because of a 





Tumours treated with the 10-mm plaque were more posteriorly located, and the plaque 
less frequently covered the entire tumour with a safety margin, making these tumours 
theoretically more vulnerable to recurrences. !e observed recurrence rates were 
low307,314,315,320,406 and comparable a&er treatment with both plaques, despite the fact that the 
10-mm plaque emits less scattered radiation. While tumours treated with the 15-mm plaque 
were larger, neither tumour size nor dose to apex was associated with local recurrence in 
multivariable modelling. An eccentric plaque location was a risk factor for a local tumour 
recurrence with both plaques, unlike the conclusion in the original paper that reported on 
the eccentric technique.310 
TTT has been associated with a relatively high risk of local recurrence with local recurrence 
rates between 7–45%.56-59,292 !e Kaplan-Meier estimate for tumour recurrence a&er TTT 
has been 26% in 5 years53 compared to a corresponding 9% rate a&er brachytherapy with 
the 10-mm plaque in Study I. !e number of risk features for growth did not predict local 
recurrence a&er treatment with the 10-mm plaque, unlike a&er TTT.56 Previous reports 
advise that small CMs with multiple risk features should be treated with methods other 
than TTT.53
Tumour location likely contributed to tumour recurrences a&er treatment with the 10-mm 
plaque. Round eccentric plaques must be used with caution310 when managing CMs which 
are located within 1 DD from the optic disc ,where it is possible that a plaque might tilt 
along the optic nerve sheath. !ree of four recurrent tumours in Study I were located less 
than 1.5 mm from the optic disc. Furthermore, peripapillary tumours have been found to 
be at a high risk of local recurrence also a&er TTT.56,292
!e frequent perifoveal location in these studies explains the high rate of developing 
radiation maculopathy and thus the e#ect on reading vision. !e unadjusted rate of 
developing radiation maculopathy was equal with both plaques (19% and 18% at 5 years), 
as estimated by cumulative incidence analysis, and thus lower than in Study I (28%). !e 
factors associated with a decrease in BCVA were tumour thickness over 3 mm, LBD over 
7 mm, and tumour location less than 1.5 mm from the foveola. Although the loss of a 
minimum vision of 20/65 (=low vision) and 20/400 (=blindness) vision was comparable 
between eyes treated with the 10-mm and 15-mm plaques overall, multivariable analysis 
showed that the distance to the foveola, which di#ered between the two groups, was a 
factor a#ecting the risk of vision loss. Controlling for this distance, the risk of losing vision 
was higher when treating with the 15-mm plaque. 
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Melanoma-related mortality a&er treatment with the 10-mm or the 15-mm plaque was 
not higher than the estimate for small (T1a, stage I) tumours in general24 despite the fact 
that a majority of tumours irradiated with the 15-mm plaque were T2a, stage IIA. !e 
2% melanoma-related mortality in Study I was comparable to that of TTT studies, where 
metastases developed in up to 5% of patients.56,57,292,332
In the literature, a 100% local tumour control has been reported a&er brachytherapy with 
the gamma ray emitter Pd103 for tumours less than 10-mm in LBD.407 However, the o#set 
was a higher rate of radiation maculopathy in 43% of eyes and radiation optic neuropathy 
in 21% of eyes irradiated with Pd103.
Comparable local tumour control and survival rates, as well as a low rate of complications 
other than radiation maculopathy and relatively good visual outcomes, might favour the 
treatment of small CMs less than 10 mm in LBD with the 10-mm Ru106 plaque over the 
15-mm plaque. !e local recurrence rate a&er treatment with the 10-mm plaque appears 
to be lower compared with TTT53,56-59,292 and not worse than with the 15-mm plaque when 
managing patients with a CM less than 10-mm in LBD. Vision loss was more probable a&er 
the 15-mm plaque when the tumours were located close to the foveola.
ϭϬ͘Ϯ͘ ^D>>&d>,KZK/>D>EKD^
A total of 3 patients with a small CM of less than 5 mm in LBD who developed metastases 
were found in the data collected from 10 ocular oncology services in Europe. A CM that 
metastasized and was less than 3 mm in LBD was not found, which suggests that 3.0 mm 
could be the limit from which a CM "rst gains its ability to metastasize, supported by the 
"nding that no tumour smaller than 3 mm in diameter has been reported to metastasize, 
and the fact that the participating centres did not "nd any such tumour in a total of 
over 10,000 treated melanomas. !is limit would, however, be subject to challenge and 
modi"cation if necessary. 
!is multicentre study further suggests that if the diagnosis cannot be otherwise obtained, 
it is safe to observe choroidal tumours until they reach 3 mm in LBD in order to verify 
growth. !is will push the size limit for early detection and treatment. !ree of the tumours 
in this study grew over the 3 mm in LBD while being observed, and, on one hand, one 
can speculate whether metastasis in these patients could have been prevented by earlier 
treatment. On the other hand, all tumours, once reasonably diagnosed as a CM, regardless 
of their size, should not continue to be observed but should be treated.
Four percent of the patients in this study did not present high-risk features for growth, and 
the frequencies of these criteria at the time of their con"rmed CM diagnosis were similar 
to those in earlier reports on small melanocytic choroidal tumours.27 A comparison of the 
number and type of risk features for growth between the SFCMs in Study III with those 
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reported for the unselected CMs in the same size range in Study I suggested that there was 
no di#erence. Additionally, the number of risk features for growth has not been associated 
with a speci"c GEP class predictive of patient survival.408 Consequently, according to both 
this present study and the "ndings from the literature, no presently known clinical tumour 
characteristics can predict the development of metastases. 
ϭϬ͘ϯ͘ /'EK^/^K&/E/W/Ed,KZK/>D>EKD^
All tumours were $at and 2 mm or less in LBD at the time of treatment, which would most 
likely correspond to the tumour size of a naevus.31 Only one patient had developed a tumour 
with 4 high-risk features, and another patient had a tumour touching the disc margin as its 
only risk feature.27,42 !e diagnosis was based on a veri"ed faster tumour growth compared 
with that of growing naevi.43 As these incipient tumours were too small for a biopsy,149,209-215 
they could only be reasonably diagnosed by observed growth. !e growth rates reported 
in this study were higher than those calculated from the reference data of naevi, while 
the TDTs were comparable with those from the reference data of melanomas, supporting 
the melanoma diagnosis of these tumours. !e patient who had a history of a previously 
treated ipsilateral CM had the shortest TDT, and, therefore, the possibility of a local tumour 
metastasis could not be excluded.
It is generally presumed that choroidal naevi emerge during puberty, and that, consequently, 
new ones should not appear during adult life. For this study, the theoretical age at which 
each tumour diagnosed as an incipient CM would not have been visible was calculated. 
With one exception, this age result was 32 years or older. In the reference group from the 
literature, none of the growing naevi had developed new risk features.43 Growth of these 
naevi had been observed in, respectively, 54%, 34%, and 19% of the patients younger than 
40 years, 41 to 60 years, and older than 60 years. Five out of the nine patients in Study 
IV were 47 to 56 years old, while the other four belonged to the oldest group. One of the 
reference studies including 217 patients with a CMs less than 3.5 mm in thickness identi"ed 
a patient age over 60 years as a new risk feature for predicting a GEP class 2.149
A high local recurrence rate is a concern a&er primary TTT treatment of CMs when 
compared with radiation therapy.52 However, such a recurrence in these incipient tumours 
would likely be less than 3 mm in LBD and therefore be highly unlikely to metastasize.61 
However, because recurrences have been reported to develop a decade a&er TTT,53,56 this 
study recommends a long-term regular follow-up for these patients, as suggested by other 
investigators.53
A further recommendation can be made that all naevi should be documented, involving 
mandatory regular check-ups to observe possible changes in lesion sizes. Risk features for 
the malignancy of choroidal lesions have been reported; however, these features generally 
develop later in the evolution of the tumour.4,103 Currently, there is no e#ective treatment for 
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metastatic disease, and it is, therefore, necessary to "nd ways to diagnose and treat patients 
with CM as early as possible to prevent the occurrence of this fatal event.
ϭϬ͘ϰ͘ ^dhz^dZE'd,^E>/D/dd/KE^
!e Helsinki University Hospital, Department of Ophthalmology, in which this study was 
conducted, is a national referral center for UMs that o#ers nationwide data. However, the 
late follow-up of patients coming from outside the Helsinki region is accomplished in other 
university hospitals or central hospitals starting 3 or 4 years a&er treatment if there is no 
evidence of recurrence. A limitation of all these retrospective studies is that a few patients 
had partially missing data for their individual visits to other university or central hospitals 
during their later follow-ups. Additionally, the number of patients in all the studies was 
small because of the rarity of this disease and the Finnish population amounting to only 
5.5 million individuals. !is small data set was compensated for by the fact that the present 
series were consecutive and population-based. 
Study II was not randomised, as the plaques were not chosen systematically, and, therefore, 
the two groups were not entirely comparable. A multivariable analysis was used to adjust 
for these di#erences, which aimed at reducing bias. Small CMs are uncommon, making 
it di'cult to organize a prospective study with an adequate sample size or, further, a 
randomised one. 
Conservatively treated patients in all the studies neither received histopathological nor 
genetic veri"cation, which, however, was in line with the usually reporting for these 
smallest tumours. 
When comparing the results of this thesis for Study I and IV with the reference data in the 
literature, it is important to take into account the many di#erences both in inclusion criteria 
and de"nitions of complications. A longer follow-up is needed in Study IV to con"rm the 
complete tumour control with TTT. 
ϭϬ͘ϱ͘ &hdhZ^Wd^
It would be ideal to aim for the earlier diagnosis of CM with a diagnostic accuracy of 100% 
as well as treatment before the tumour reaches metastatic capacity. Choroidal naevi that 
show no risk features should be regularly monitored and treated when tumours show 
growth before their diameters are over 3 mm. If the tumours are located outside the 
posterior pole, they should be treated with less delay. !is thesis reports reference rates for 
tumour growth and doubling times, which could be used for earlier diagnostics. Newer 
imaging techniques provide new information and show new risk factors for choroidal 
lesions, aiming at an earlier detection.
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It is likely that, in the near future, radiotherapy will remain as the principal treatment 
option for small CMs. However, an earlier diagnosis could possibly enable the safe use of 
TTT for extremely small $at tumours despite the criticism against TTT’s high recurrence 
rates for thicker tumours. However, further studies and longer follow-ups are needed to 
con"rm the e'cacy of TTT when treating these incipient melanomas.
Metastatic disease constitutes a signi"cant cause of mortality, including in patients with 
a small CM. It will be necessary, in the future, to detect and manage subclinical distant 
metastasis to ultimately control this malignant disease. 
With earlier local treatment combined with future systemic therapies for subclinical 
metastasis, the improved survival of patients with UM will be accomplished. E#ective 
local treatment modalities with e#ective tumour control are available for the appropriate 
patient selection. However, the prevention of dissemination will be the key to providing the 
most ideal prognosis. Currently, the most e#ective measure to minimize poor prognosis 





I. An acceptable local tumour control, a low rate of side-e#ects other than radiation 
maculopathy, and the e#ective preservation of vision support the use of a 10-mm 
ruthenium106 plaque in treating small CMs.
II. 10-mm ruthenium106 plaque contributes to improved visual preservation without 
increasing the local recurrence rate, particularly with tumours close to the fovea, and 
may therefore be preferable to the 15-mm plaque.
III. Small CMs of less than 3 mm in LBD are highly unlikely to metastasize, and no 
known clinical risk feature can predict the development of metastases from a tumour 
of this size.
IV. Small incipient CMs can be di#erentiated from small naevi by their growth rates, 
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